Role of complement in innate and autoimmunity

Journal of Nephrology

Volumn 18, Issue 6, 2005, Pages 642-653

  Seelen, Marc A J ^a   Roos, Anja ^a   Daha, Mohamed R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Autoimmunity; Complement; Innate immunity; Kidney diseases

Indexed keywords

AUTOANTIBODY; CALRETICULIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; CYTOTOXIC AGENT; IMMUNOCONGLUTININ; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LECTIN; MANNOSE BINDING LECTIN; MANNOSE BINDING PROTEIN; OPSONIN; SERINE PROTEINASE; STEROID;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BINDING AFFINITY; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MORTALITY; NONHUMAN; PHAGOCYTE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME; VASCULAR DISEASE;

ANIMALS; AUTOIMMUNITY; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, NATURAL; KIDNEY DISEASES;

EID: 30644471421     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140-4.
2. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-66.
3. Castellano G, Woltman AM, Nauta AJ, Roos A, Trouw LA, Seelen MA, Schena FP, Daha MR, van Kooten C. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 2004; 103: 3813-20.
4. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-7.
5. Nagaki K, Hiramatsu S, Inai S, Sasaki A. The effect of aging on complement activity (CH50) and complement protein levels. J Clin Lab Immunol 1980; 3: 45-50.
6. Ip WK, To YF, Cheng SK, Lau YL. Serum mannose-binding lectin levels and mbl2 gene polymorphisms in different age and gender groups of southern Chinese adults. Scand J Immunol 2004; 59: 310-4.
7. Spath PJ, Sjoholm AG, Fredrikson GN, Misiano G, Scherz R, Schaad UB, Uhring-Lambert B, Hauptmann G, Westberg J, Uhlen M, Wadelius C, Truedsson L. Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol 1999; 118: 278-84.
8. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O. Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature. J Clin Lab Anal 2004; 18: 9-13.
9. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21: 547-78.
10. Holmskov U, Malhotra R, Sim RB, Jensenius JC. Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today 1994; 15: 67-74.
11. Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 1992; 90: 31-5.
12. Aittoniemi J, Miettinen A, Laippala P, Isolauri E, Viikari J, Ruuska T, Soppi E. Age-dependent variation in the serum concentration of mannan-binding protein. Acta Paediatr 1996; 85: 906-9.
13. Hansen S, Holmskov U. Structural aspects of collectins and receptors for collectins. Immunobiology 1998; 199: 165-89.
14. Hansen S, Thiel S, Willis A, Holmskov U, Jensenius JC. Purification and characterization of two mannan-binding lectins from mouse serum. J Immunol 2000; 164: 2610-8.
15. Sastry K, Herman GA, Day L, Deignan E, Bruns G, Morton CC, Ezekowitz RA. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989; 170: 1175-89.
16. Sastry K, Zahedi K, Lelias JM, Whitehead AS, Ezekowitz RA. Molecular characterization of the mouse mannose-binding proteins. The mannose-binding protein A but not C is an acute phase reactant. J Immunol 1991; 147: 692-7.
17. Madsen HO, Carred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-20.
18. Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, Summerfield JA. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991; 337: 1569-70.
19. Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, Summerfield JA, Turner MW. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992; 1: 709-15.
20. Madsen HO, Garred P, Kurtzhals JA, Lamm LU, Ryder LP, Thiel S, Svejgaard A. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994; 40: 37-44.
21. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998; 161: 3169-75.
22. Fraser IP, Koziel H, Ezekowitz RA. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 1998; 10: 363-72.
23. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003; 37: 1496-505.
24. Kuhlman M, Joiner K, Ezekowitz RA. The human mannose-binding protein functions as an opsonin. J Exp Med 1989; 169: 1733-45.
25. Nauta AJ, Raaschou-Jensen N, Roos A, Daha MR, Madsen HO, Borrias-Essers MC, Ryder LP, Koch C, Garred P. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003; 33: 2853-63.
26. Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, van Kooten C, Roos A. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004; 173: 3044-50.
27. Palaniyar N, Nadesalingam J, Clark H, Shih MJ, Dodds AW, Reid KB. Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin. J Biol Chem 2004; 279: 32728-36.
28. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989; 2: 1236-9.
29. Ezekowitz RA. Role of the mannose-binding lectin in innate immunity. J Infect Dis 2003; 187 (suppl 2): S335-9.
30. Garred P, Madsen HO, Hofmann B, Svejgaard A. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 1995; 346: 941-3.
31. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose-binding-protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314: 1229-32.
32. Mead R, Jack D, Pembrey M, Tyfield L, Turner M. Mannose-binding lectin alleles in a prospectively recruited UK population. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Lancet 1997; 349: 1669-70.
33. Garred P, Strom J, Quist L, Taaning E, Madsen HO. Association of marmose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003; 188: 1394-403.
34. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104: 431-7.
35. Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001; 2: 442-50.
36. Nagy A, Kozma GT, Keszei M, Treszl A, Falus A, Szalai C. The development of asthma in children infected with Chlamydia pneumoniae is dependent on the modifying effect of mannose-binding lectin. J Allergy Clin Immunol 2003; 112: 729-34.
37. Yang IA, Seeney SL, Wolter JM, Anders EM, McCormack JG, Tunnicliffe AM, Rabnott GC, ShawJG, Dent AG, Kim ST, Zimmerman PV, Fong KM. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun 2003; 4: 269-74.
38. Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A. Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet 1994; 21: 125-31.
39. Soborg C, Madsen HO, Andersen AB, Lillebaek T, Kok-Jensen A, Garred P. Mannose-binding lectin polymorphisms in clinical tuberculosis. J Infect Dis 2003; 188: 777-82.
40. Boniotto M, Braida L, Pirulli D, Arraes L, Amoroso A, Crovella S. MBL2 polymorphisms are involved in HIV-1 infection in Brazilian perinatally infected children. AIDS 2003; 17: 779-80.
41. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, Svejgaard A. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349: 236-40.
42. Garred P, Richter C, Andersen AB, Madsen HO, Mtoni I, Svejgaard A, Shao J. Mannan-binding lectin in the sub-Saharan HIV and tuberculosis epidemics. Scand J Immunol 1997; 46: 204-8.
43. Amoroso A, Berrino M, Boniotto M, Crovella S, Palomba E, Scarlatti G, Serra C, Tovo PA, Vatta S. Polymorphism at codon 54 of mannose-binding protein gene influences AIDS progression but not HIV infection in exposed children. AIDS 1999; 13: 863-4.
44. Kilpatrick DC, McLintock LA, Allan EK, Copland M, Fujita T, Jordanides NE, Koch C, Matsushita M, Shiraki H, Stewart K, Tsujimura M, Turner ML, Franklin IM, Holyoake TL. No strong relationship betweem mannan-binding lectin or plasma ficolins and chemotherapy-related infections. Clin Exp Immunol 2003; 134: 279-84.
45. Sasaki K, Tsutsumi A, Wakamiya N, Ohtani K, Suzuki Y, Watanabe Y, Nakayama N, Koike T. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol 2000; 35: 960-5.
46. Thomas HC, Foster GR, Sumiya M, McIntosh D, Jack DL, Turner MW, Summerfield JA. Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet 1996; 348: 1417-9.
47. Yuen MF, Lau CS, Lau YL, Wong WM, Cheng CC, Lai CL. Mannose-binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999; 29: 1248-51.
48. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37: 733-7.
49. Ip WY, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004; 190: 632-40.
50. Barton A, Platt H, Salway F, Symmons D, Lunt M, Worthington J, Silman A. Polymorphisms in the mannose-binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. J Rheumatol 2004; 31: 442-7.
51. Garred P, Madsen HO, Marquart H, Hansen TM, Sorensen SF, Petersen J, Volck B, Svejgaard A, Graudal NA, Rudd PM, Dwek RA, Sim RB, Andersen V. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheumatol 2000; 27: 26-34.
52. Graudal NA, Homann C, Madsen HO, Svejgaard A, Jurik AG, Graudal HK, Garred P. Mannan-binding lectin in rheumatoid arthritis. A longitudinal study. J Rheumatol 1998; 25: 629-35.
53. Kilpatrick DC. Mannan-binding protein in sera positive for rheumatoid factor. Br J Rheumatol 1997; 36: 207-9.
54. Stanworth SJ, Donn RP, Hassall A, Dawes P, Ollier W, Snowden N. Absence of an association between mannose-binding lectin polymorphism and rheumatoid arthritis. Br J Rheumatol 1998; 37: 186-8.
55. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1: 237-43.
56. Parekh RB, Dwek RA, Sutton B. J, Fernandes DL, Leung A, Stanworth D, Rademacher TW, T Mizuochi T, Taniguchi T, Matsuta K et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316: 452-7.
57. Ji H, Ohmura & Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D. Arthritis critically dependent on innate immune system players. Immunity 2002; 16: 157-68.
58. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990; 89: 209-15.
59. Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 1980; 66: 1432-6.
60. Stad RK, Bruijn JA, Gijlswijk-Janssen DJ, van Es LA, Daha MR. An acute model for IgA-mediated glomerular inflammation in rats induced by monoclonal polymeric rat IgA antibodies. Clin Exp Immunol 1993; 92: 514-21.
61. Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59: 1077-85.
62. Russell MW, Kilian M, Lamm ME. Biological activity of IgA. In: Ogra PLO, Mestecky J (Eds). Mucosal immunology. San Diego: Academic Press 1999; 225.
63. Miyazaki R, Kuroda M, Akiyama T, Otani I, Tofuku Y, Takeda R. Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin Nephrol 1984; 21: 335-40.
64. Hisano S, Matsushita M, Fujita T, Endo Y, Takebayashi S. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 2001; 38: 1082-8.
65. Roos A, Bouwman LH, Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861-8.
66. Hansch GM. The role of complement in mesangial cell damage. Nephrol Dial Transplant 1993; 8: 4-5.
67. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994; 330: 1871-9.
68. Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum 1982; 25: 55-60.
69. Ginzler EM. Clinical manifestations of disease activity, its measurement, and associated morbidity in systemic lupus erythematosus. Curr Opin Rheumatol 1991; 3: 780-8.
70. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000; 39: 399-406.
71. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481-90.
72. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199: 265-85.
73. Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. Curr Opin Rheumatol 2002; 14: 498-503.
74. Siegert CE, Daha MR, Swaak AJ, van der Voort EA, Breedveld FC. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic 1upus erythematosus. Clin Immunol Immunopathol 1993; 67: 204-9.
75. Finkelstein Y, Adler Y, Harel L, Nussinovitch M, Youinou P. Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block. Ann Med Interne (Paris) 1997; 148: 205-8.
76. GinsbergJS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993; 81: 2958-63.
77. Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 851-6.
78. Siegert C, Daha M, Westedt ML, van der Voort E, Breedveld F. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18: 230-4.
79. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990; 89: 411-9.
80. Smeenk R, Brinkman K, van den BH, Termaat RM, Berden J, Nossent H, Swaak T. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9: 100-10.
81. Dighiero G, Lymberi P, Guilbert B, Ternynck T, Avrameas S. Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann N Y Acad Sci 1986; 475: 135-45.
82. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
83. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-24.
84. Berden JH. Lupus nephritis. Kidney Int 1997; 52: 538-58.
85. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72: 113-24.
86. Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 1990; 150: 849-53.
87. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-50.
88. Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH. Repeated renal biopsy in proliferative lupus nephritis - predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29: 693-9.
89. Mannik M, Wener MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40: 1504-11.
90. Trouw LA, Seelen MA, Visseren R, Duijs JM, Benediktsson H, de Heer E, Roos A, van Kooten C, Daha MR. Anti-C1q autoantibodies in murine lupus nephritis. Clin Exp Immunol 2004; 135: 41-8.
91. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977; 59: 90-6.
92. Coremans IE, Spronk PE, Bootsma H, Daha MR, van der Voort EA, Kater L, Breedveld FC, Kallenberg CG. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995; 26: 595-601.
93. Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004; 13: 36-44.
94. Coremans IE, Bruijn JA, de Heer E, van der Voort EA, Breedveld FC, Daha MR. Stabilization of glomerular deposits of C1q antibodies against C1q in mice. J Clin Lab Immunol 1995; 44: 47-61.
95. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, Kooten CC, Daha MR. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679-88.
96. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004; 22: 431-56.
97. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology 2002; 205: 395-406.
98. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-30.
99. Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003; 24: 148-54.
100. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM. C1q and mannose-binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781-95.
101. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56-9.
102. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun 2002; 19: 147-54.
103. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-40.
104. Davies EJ, Snowden N, Hillarby MC, Carthy D, Grennan DM, Thomson W, Ollier WE. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995; 38: 110-4.
105. Davies EJ, Teh LS, Ordi-Ros J, Snowden N, Hillarby MC, Hajeer A, Donn R, Perez-Pemen P, Vilardell-Tarres M, Ollier WE. A dysfunctional allele of the mannose-binding protein gene associates with systemic lupus erythematosus in a Spanish population. J Rheumatol 1997; 24: 485-8.
106. Mok MY, Jack DL, Lau CS, Fong DY, Turner MW, Isenberg DA, Lydyard PM. Antibodies to mannose-binding lectin in patients with systemic lupus erythematosus. Lupus 2004; 13: 522-8.
107. Sullivan KE, Wooten C, Goldman D, Petri M. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 2046-51.
108. Horiuchi T, Tsukamoto H, Morita C, Sawabe T, Harashima S, Nakashima H, Miyahara H, Hashimura C, Kondo M. Mannose-binding lectin (MBL) gene mutation is not a risk factor for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Japanese. Genes Immun 2000; 1: 464-6.
109. Lhotta K, Wurzner R, Konig P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant 1999; 14: 881-6.
110. Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001; 104: 1413-8.
111. Sund S, Hovig T, Reisaeter AV, Scott H, Bentdal O, Mollues TE. Complement activation in early protocol kidney graft biopsies after living-donor transplantation. Transplantation 2003; 75: 1204-13.
112. Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, Poulsen PL. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 4857-61.
113. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004; 53: 1570-6.
114. Best LG, Davidson M, North KE, MacCluer JW, Zhang Y, Lee ET, Howard BV, DeCroo S, Ferrell RE. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation 2004; 109: 471-5.
115. Roos A, Trouw LA, Ioan-Facsinay A, Daha MR, Verbeek JS. Complement system Fc receptors: Genetics. In Cooper DN (Ed). Nature encyclopedia of the human genome. London: Nature Publishing Group 2003; 914-27.
116. Petersen SV, Thiel S, Jensen L, Steffensen R, Jensenius JC. An assay for the mannan-binding lectin pathway of complement activation. J Immunol Methods 2001; 257: 107-16.
117. Ikeda K, Sannoh T, Kawasaki N, Kawasaki T, Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J Biol Chem 1987; 262: 7451-4.
118. Kuipers S, Aerts PC, Sjoholm AG, Harmsen T, van Dijk H. A hemolytic assay for the estimation of functional mannose-binding lectin levels in human serum. J Immunol Methods 2002; 268: 149-57.
119. Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC, Fallaux-van den Houten FC, Klar-Mohamad N, Hack CE, Tilanus MG, Daha MR. Functional characterization of the lectin pathway of complement in human serum. Mol Immunol 2003; 39: 655-68.
120. Super M, Levinsky RJ, Turner MW. The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations. Clin Exp Immunol 1990; 79: 144-50.